Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
January 13 2021 - 4:01PM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
clinical-stage biotechnology company focused on the development of
novel therapies with the potential to improve the lives of patients
with immune-mediated diseases, today announced that it intends to
offer and sell, subject to market and other conditions, shares of
its common stock in an underwritten public offering. Aldeyra also
expects to grant the underwriters a 30-day option to purchase up to
an additional 15% of the amount of shares of common stock sold in
the offering, at the public offering price, less the underwriting
discounts and commissions. There can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering. All of the shares in the offering are to be
sold by Aldeyra, with net proceeds to be used for the continued
development of Aldeyra's lead compound, reproxalap, and its other
product candidates, as well as for working capital and other
general corporate purposes.
Jefferies LLC and SVB Leerink LLC are acting as joint
book-running managers for the offering.
The shares of common stock described above are being offered by
Aldeyra pursuant to a shelf registration statement on Form S-3
previously filed with the Securities and Exchange Commission (SEC)
and declared effective by the SEC on July 27, 2018. A preliminary
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the
SEC’s web site at www.sec.gov. When
available, copies of the preliminary prospectus supplement relating
to these securities may also be obtained by sending a request to:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, New York 10022, by
telephone at 877-821-7388 or by email at
Prospectus_Department@Jefferies.com, or from SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, Massachusetts 02110, by telephone at 1-800-808-7525, ext.
6132, or by email at syndicate@svbleerink.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead investigational compounds, reproxalap and
ADX-629, target RASP (reactive aldehyde species), which are
elevated in ocular and systemic inflammatory disease and result in
cytokine release via activation of a broad array of inflammatory
factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Reproxalap is being evaluated in Phase 3 clinical trials in
patients with dry eye disease and allergic conjunctivitis. The
company’s clinical pipeline also includes ADX-2191, a dihydrofolate
reductase inhibitor in Phase 3 testing for proliferative
vitreoretinopathy, and ADX-1612, a chaperome inhibitor in
development for COVID-19 and ovarian cancer.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, including but not limited to statements regarding the
public offering and the anticipated use of the proceeds thereof.
These forward-looking statements are subject to a number of risks,
including the satisfaction of customary closing conditions related
to the proposed public offering and the risk factors set forth from
time to time in Aldeyra’s SEC filings, including but not limited to
the risks that are described in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of Aldeyra’s Annual Report on Form
10-K for the year ended December 31, 2019 and Aldeyra’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2020 which
are on file with the SEC and available on the SEC’s website at
www.sec.gov. In addition to the risks described above and in
Aldeyra’s other filings with the SEC, other unknown or
unpredictable factors also could affect Aldeyra’s results. No
forward-looking statements can be guaranteed and actual results may
differ materially from such statements. The information in this
release is provided only as of the date of this release, and
Aldeyra undertakes no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210113005865/en/
Corporate: David McMullin Aldeyra Therapeutics, Inc. Tel:
781-761-4904 ext. 218 dmcmullin@aldeyra.com Investor & Media:
Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Sep 2023 to Sep 2024